165 related articles for article (PubMed ID: 7791265)
1. [Comparison of complement activation between tuberculous and malignant pleuritis].
Hidaka K; Abe M; Tanaka T; Mitsuyama T; Hara N; Hara N
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Apr; 33(4):379-83. PubMed ID: 7791265
[TBL] [Abstract][Full Text] [Related]
2. Pleural SC5b-9 in differential diagnosis of tuberculous, malignant, and other effusions.
Hara N; Abe M; Inuzuka S; Kawarada Y; Shigematsu N
Chest; 1992 Oct; 102(4):1060-4. PubMed ID: 1395743
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of pleural complement activation products in differentiating tuberculosis and malignant effusions.
Porcel JM; Vives M; Gázquez I; Vicente de Vera MC; Pérez B; Rubio M
Int J Tuberc Lung Dis; 2000 Jan; 4(1):76-82. PubMed ID: 10654648
[TBL] [Abstract][Full Text] [Related]
4. Complement components and their activation products in pleural fluid.
Salomaa ER; Viander M; Saaresranta T; Terho EO
Chest; 1998 Sep; 114(3):723-30. PubMed ID: 9743157
[TBL] [Abstract][Full Text] [Related]
5. Complement activation in platelet concentrates is surface-dependent and modulated by the platelets.
Gyongyossy-Issa MI; McLeod E; Devine DV
J Lab Clin Med; 1994 Jun; 123(6):859-68. PubMed ID: 8201264
[TBL] [Abstract][Full Text] [Related]
6. High levels of complement breakdown products in tuberculous pleural effusions.
Lew DP; Perrin LH; Vassalli JD; Suter S; Lambert PH; Waldvogel FA
Clin Exp Immunol; 1983 Jun; 52(3):569-74. PubMed ID: 6603298
[TBL] [Abstract][Full Text] [Related]
7. [Immunologic study of pleural neoplastic effusions: Detection of immune complexes and complement activation].
Kaelin R; Docquier C; Lew D; Carpentier N; Lambert PH; Waldvogel FA
Schweiz Med Wochenschr; 1978 Dec; 108(49):1971-3. PubMed ID: 749195
[TBL] [Abstract][Full Text] [Related]
8. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis.
Brodeur JP; Ruddy S; Schwartz LB; Moxley G
Arthritis Rheum; 1991 Dec; 34(12):1531-7. PubMed ID: 1747138
[TBL] [Abstract][Full Text] [Related]
9. Complement activation during CAPD.
Young GA; Kendall S; Brownjohn AM
Nephrol Dial Transplant; 1993; 8(12):1372-5. PubMed ID: 8159307
[TBL] [Abstract][Full Text] [Related]
10. Demonstration of apoptosis-associated cleavage products of DNA, complement activation products SC5b-9 and C3d/dg, and immune complexes CIC-C3d, CIC-IgA, and CIC-IgG in the urine of patients with membranous glomerulonephritis.
Kotnik V; Premzl A; Skoberne M; Malovrh T; Kveder R; Kaplan-Pavlovcic S; Kotnik A; Stiblar-Martincic D
Croat Med J; 2003 Dec; 44(6):707-11. PubMed ID: 14652883
[TBL] [Abstract][Full Text] [Related]
11. Differentiating tuberculous from malignant pleural effusions: a scoring model.
Porcel JM; Vives M
Med Sci Monit; 2003 May; 9(5):CR175-80. PubMed ID: 12761453
[TBL] [Abstract][Full Text] [Related]
12. [Determination and significance of interleukin-16 in tuberculous and malignant pleural effusion].
Huang ZX; Shi HZ; Kang LF; Qin XJ; Mo WN; Chen YQ
Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):199-201. PubMed ID: 16624150
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous measurement of T-helper 1 cytokines in tuberculous pleural effusion.
Hiraki A; Aoe K; Matsuo K; Murakami K; Murakami T; Onoda T; Sugi K; Takeyama H; Eda R
Int J Tuberc Lung Dis; 2003 Dec; 7(12):1172-7. PubMed ID: 14677892
[TBL] [Abstract][Full Text] [Related]
14. Differential cytokine levels and immunoreactivities against Mycobacterium tuberculosis antigens between tuberculous and malignant effusions.
Yang CS; Lee JS; Lee HM; Shim TS; Son JW; Jung SS; Kim JS; Song CH; Kim HJ; Jo EK
Respir Med; 2008 Feb; 102(2):280-6. PubMed ID: 17933504
[TBL] [Abstract][Full Text] [Related]
15. Complement activation and immune complexes in juvenile rheumatoid arthritis.
Jarvis JN; Pousak T; Krenz M; Iobidze M; Taylor H
J Rheumatol; 1993 Jan; 20(1):114-7. PubMed ID: 8441140
[TBL] [Abstract][Full Text] [Related]
16. [Lymphocyte chemotactic factor in tuberculous pleural effusion].
Naito T; Ohtsuka M; Ishikawa H; Satoh H; Hasegawa S
Kekkaku; 1998 Apr; 73(4):307-14. PubMed ID: 9613051
[TBL] [Abstract][Full Text] [Related]
17. Pleural fluid complement, complement conversion, and immune complexes in immunologic and nonimmunologic diseases.
Hunder GG; McDuffie FC; Huston KA; Elveback LR; Hepper NG
J Lab Clin Med; 1977 Dec; 90(6):971-80. PubMed ID: 597373
[TBL] [Abstract][Full Text] [Related]
18. Macrophage-derived chemokine in malignant and tuberculous pleural effusions.
Okamoto M; Imaizumi K; Hasegawa Y; Hashimoto N; Sumida A; Shibazaki M; Takagi K; Shimokata K; Kawabe T
Respirology; 2007 Jul; 12(4):581-4. PubMed ID: 17587426
[TBL] [Abstract][Full Text] [Related]
19. Decreased heat-labile opsonic activity and complement levels associated with evidence of C3 breakdown products in infected pleural effusions.
Lew PD; Zubler R; Vaudaux P; Farquet JJ; Waldvogel FA; Lambert PH
J Clin Invest; 1979 Feb; 63(2):326-34. PubMed ID: 429556
[TBL] [Abstract][Full Text] [Related]
20. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement.
Buyon JP; Tamerius J; Belmont HM; Abramson SB
Arthritis Rheum; 1992 Sep; 35(9):1028-37. PubMed ID: 1418018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
